Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 1, 2015Lenvatinib, investigated in patients with metastatic renal cancer, showed an increase in progression-free survival (PFS)
Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival...
-
May 30, 2015Data from pivotal study for eribulin to be presented during oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced...
-
May 14, 2015Company demonstrates dedication to rare cancers
Eisai Inc. announced today the presentation of seven abstracts at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) highlighting the breadth of the company's oncology...
-
Apr 30, 2015
Eisai Inc. and Eisai Co., Ltd. have entered into a settlement agreement with Glenmark Pharmaceuticals, Ltd., Glenmark Generics Ltd., and Glenmark Generics, Inc., USA ("Glenmark"), to resolve their...
-
Apr 15, 2015
Helsinn Group and Eisai Inc. jointly announced today the decision of the National Comprehensive Cancer Network (NCCN) to include AKYNZEO® in the 2015 NCCN Antiemesis Guidelines as a recommended...